Sustained Aeration of Infant Lungs Trial (SAIL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02139800 |
|
Recruitment Status :
Completed
First Posted : May 15, 2014
Results First Posted : June 25, 2020
Last Update Posted : April 6, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
This study is a 2-arm randomized, controlled, multi-center clinical trial to determine which of two strategies at birth are best to optimally aerate the lung of preterm infants. Specifically we will determine in 600 infants of 23-26 weeks gestational age (GA) requiring respiratory support at birth which of two lung opening strategies - either a standard PEEP/CPAP of 5-7 cm H2O in the delivery room (DR), as compared to early lung recruitment using Sustained Inflation (SI) in the DR, will result in a lower rate of the combined endpoint of death or bronchopulmonary dysplasia (BPD) at 36 weeks gestational age.
Hypotheses:
- Early lung recruitment with SI superimposed upon standard PEEP/CPAP in the DR will reduce the need for mechanical ventilation in the first seven days of life, and reduce need for surfactant use; and
- A policy of DR SI on standard PEEP/CPAP recruitment will confer better outcomes at 36 weeks post-menstrual age (PMA) than standard PEEP/CPAP
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Preterm Birth Extreme Prematurity | Procedure: Sustained Inflation Procedure: Standard of Care | Not Applicable |
The SAIL trial aims to provide evidence for changing policy or standard of care. The context of this trial is an unacceptable rate of poor long-term outcomes of preterm infants born as Extremely Low Gestational Age Newborns (ELGAN) <1000 g birthweight (BW), but especially for those born between 23-26 weeks' gestational age (GA). Such infants are the most vulnerable and immature in all organ systems, including the lungs and the brain. These infants are at high risk of death and bronchopulmonary dysplasia (BPD) during their initial hospitalization, neurodevelopmental impairment (NDI) and pulmonary problems in infancy and childhood.
The SAIL trial focuses on facilitating the difficult transition of these most vulnerable infants from a liquid filled in-utero lung to an ex-utero air-filled lung. Sustained Inflation (SI) is a promising delivery room (DR) intervention, with evidence of short-term efficacy with minimal risk of additional harm beyond current standard accepted Newborn Resuscitation Program (NRP) Guidelines. This protocol proposes a fully informed consenting procedure. We propose to evaluate the impact of a SI in the DR on the need for mechanical ventilation in the first week of life which would also impact mortality rates and the incidence and severity of BPD.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 460 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Sustained Aeration of Infant Lungs Trial |
| Actual Study Start Date : | August 27, 2014 |
| Actual Primary Completion Date : | February 15, 2018 |
| Actual Study Completion Date : | March 23, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Control Arm-Standard of care
Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
|
Procedure: Standard of Care
Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention |
|
Experimental: Sustained Intervention
Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
|
Procedure: Sustained Inflation
The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds |
- Combined Outcome of Death or Bronchopulmonary Dysplasia [ Time Frame: 36 weeks ]To determine in infants born at 23-26 weeks gestational age requiring respiratory support at birth, which of two treatment strategies when compared, results in a lower rate of the combined endpoint of death or bronchopulmonary dysplasia.
- Oxygen Profile Over First 24 Hours [ Time Frame: First 24 hours post delivery ]Oxygen profile over first 24 hours post delivery room using hourly FiO2 records
- Oxygen Profile With Highest FiO2 Level up to 48 Hours [ Time Frame: 48 hours of life ]Highest FiO2 level recorded during the first 48 hours post DR
- Heart Rate in the Delivery Room (DR) [ Time Frame: First 30 seconds of life in DR ]Categorical variable with 3 levels: <60, 60-100, >100
- Detailed Status on Departure From the Delivery Room (DR) [ Time Frame: Resuscitation time will vary - 1 to 30 minutes ]Type of respiratory support (CPAP, PPV) and Fraction of Inspired Oxygen (FiO2) on departure from DR
- Use of Inotropes on Arrival in NICU [ Time Frame: First 48 hours of life ]Circulatory support post-delivery room
- Need for Intubation in Delivery Room [ Time Frame: First 30 seconds to 24 hours of life ]Need for intubation in delivery room during the first 30 seconds to 24 hours of age
- Pressure-volume Characteristics in the Delivery Room (DR) [ Time Frame: Expected average 30 minutes ]Pressure-volume characteristics in the Delivery room (DR) expected within 30 minutes
- Pneumothorax or New Chest Drains in the First 48 Hours of Life [ Time Frame: First 48 hours of life ]Chest x-ray reports showing pneumothorax or new chest drains in the first 48 hours of life
- Duration of Any Chest Drain In-situ Post-DR [ Time Frame: During hospitalization - up to 36 weeks Post Menstrual Age (PMA) ]Duration of any chest drain in-situ post-DR during hospitalization - up to 36 weeks Post Menstrual Age (PMA)
- Intraventricular Hemorrhage by All Grades [ Time Frame: 48 hours to 10 days ]Head ultrasound and/or MRI findings of intraventricular hemorrhage by all grades focusing on grades 3 and 4 by 48 hour and by day 10
- Chest X-ray Between Days 7-10 [ Time Frame: First 7-10 days of life ]Chest x-ray between the first 7-10 days of life
- Death or Need for Positive Pressure Ventilation [ Time Frame: First 7 days of life ]Death or need for positive pressure ventilation during the first 7 days of life
- Highest FiO2 and Area Under the FiO2 Curve for the First Week of Life [ Time Frame: First 7 days of life ]Highest FiO2 and Area under the FiO2 curve during the first 7 days of life
- Pneumothorax and Pulmonary Interstitial Emphysema (PIE) [ Time Frame: First 10 days of life ]Pneumothorax and pulmonary interstitial emphysema (PIE) during the first 10 days of life
- Survival to Discharge Home Without BPD, Retinopathy of Prematurity (Grades 3 & 4), or Significant Brain Abnormalities on Head Ultrasound [ Time Frame: Expected discharge between 36 - 40 weeks PMA ]Survival to discharge home without BPD, retinopathy of prematurity (grades 3 & 4), or significant brain abnormalities on head ultrasound with an expected discharge between 36-40 weeks PMA
- Duration of Respiratory Support (Ventilation, CPAP, Supplemental Oxygen) [ Time Frame: During hospitalization - up to 36 weeks Post Menstrual Age (PMA) ]Duration of respiratory support (ventilation, CPAP, supplemental oxygen) during hospitalization upto 36 weeks Post Menstrual Age (PMA)
- Death in Hospital [ Time Frame: During expected hospitalization 23 - 40 weeks PMA ]Death in hospital during expected hospitalization of 23-40 weeks PMA
- Retinopathy of Prematurity (ROP) Stage 3 or Greater Requiring Treatment [ Time Frame: 36 weeks ]Retinopathy of prematurity (ROP) stage 3 or greater requiring treatment at 36 weeks
- Use of Postnatal Steroids for Treatment of BPD [ Time Frame: During hospitalization - up to 36 weeks Post Menstrual Age (PMA) ]Use of postnatal steroids for treatment of BPD during hospitalization up to 36 weeks Post Menstrual Age (PMA)
- Length of Hospital Stay [ Time Frame: Average discharge between 36 - 40 weeks PMA ]Length of hospital stay with average discharge between 36-40 weeks PMA
- Neurodevelopmental and Respiratory Outcome at 22-26 Months Corrected Gestational Age [ Time Frame: 22-26 months corrected gestational age ]Neurodevelopmental and respiratory outcome at 22-26 months corrected gestational age
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 23 Weeks to 26 Weeks (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Gestational age (GA) at least 23 weeks but less than 27 completed weeks by best obstetrical estimate
- Requiring resuscitation/respiratory intervention at birth -"apneic, labored breathing, gasping" (as defined in NRP 2011 AAP 6th Edition p.45)
Exclusion Criteria:
- Considered non-viable by the attending neonatologist
- Refusal of antenatal informed consent
- Known major anomalies, pulmonary hypoplasia
- Mothers who are unable to consent for their medical care and who do not have a surrogate guardian will not be approached for consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02139800
Show 21 study locations
| Principal Investigator: | Haresh Kirpalani, BM, MSc | Children's Hospital of Philadelphia | |
| Principal Investigator: | Peter Davis, MD, FRAXP | Royal Women's Hospital, Melbourne, Australia | |
| Principal Investigator: | Helmut Hummler, MD | Children's Hospital, University of Ulm, Ulm Germany | |
| Principal Investigator: | Martin Keszler, MD | Women & Infants Hospital of Rhode Island, Providence, RI | |
| Principal Investigator: | GianLuca Lista, MD | Ospedale dei Bambini, Milan Italy | |
| Principal Investigator: | Arjan te_Pas, MD | Leiden University Medical Center, Leiden, Netherlands |
Documents provided by University of Pennsylvania:
| Responsible Party: | University of Pennsylvania |
| ClinicalTrials.gov Identifier: | NCT02139800 |
| Other Study ID Numbers: |
819208 1U01HD072906-01A1 ( U.S. NIH Grant/Contract ) |
| First Posted: | May 15, 2014 Key Record Dates |
| Results First Posted: | June 25, 2020 |
| Last Update Posted: | April 6, 2023 |
| Last Verified: | April 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
|
Neonatal resuscitation Extreme Low Gestational Age Newborn (ELGAN) Delivery Room |
Continuous positive airway pressure (CPAP) Positive pressure ventilation (PPV) Sustained inflation |
|
Premature Birth Obstetric Labor, Premature Obstetric Labor Complications |
Pregnancy Complications Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases |